These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8712712)

  • 21. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
    Boven E; Nauta MM; Schlüper HM; Erkelens CA; Pinedo HM
    Cancer Chemother Pharmacol; 1986; 18(2):124-8. PubMed ID: 3098444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A calicheamicin conjugate with a fully humanized anti-MUC1 antibody shows potent antitumor effects in breast and ovarian tumor xenografts.
    Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Shochat D; Mountain A
    Bioconjug Chem; 2005; 16(2):354-60. PubMed ID: 15769089
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts.
    Giavazzi R; Garofalo A; Ferri C; Lucchini V; Bone EA; Chiari S; Brown PD; Nicoletti MI; Taraboletti G
    Clin Cancer Res; 1998 Apr; 4(4):985-92. PubMed ID: 9563894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
    Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
    Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.
    Calabresi P; Goulette FA; Darnowski JW
    Cancer Res; 2001 Sep; 61(18):6816-21. PubMed ID: 11559556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
    Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
    Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
    Kelland LR
    Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline) sulfatooxovanadium(IV) (METVAN [VO(SO4)(Me2-Phen)2]).
    Narla RK; Chen CL; Dong Y; Uckun FM
    Clin Cancer Res; 2001 Jul; 7(7):2124-33. PubMed ID: 11448932
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.
    Bacherikov VA; Chou TC; Dong HJ; Zhang X; Chen CH; Lin YW; Tsai TJ; Lee RZ; Liu LF; Su TL
    Bioorg Med Chem; 2005 Jun; 13(12):3993-4006. PubMed ID: 15911312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors.
    Rewcastle GW; Murray DK; Elliott WL; Fry DW; Howard CT; Nelson JM; Roberts BJ; Vincent PW; Showalter HD; Winters RT; Denny WA
    J Med Chem; 1998 Feb; 41(5):742-51. PubMed ID: 9513602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo toxicity, pharmacokinetics, and anticancer activity of Genistein linked to recombinant human epidermal growth factor.
    Uckun FM; Narla RK; Zeren T; Yanishevski Y; Myers DE; Waurzyniak B; Ek O; Schneider E; Messinger Y; Chelstrom LM; Gunther R; Evans W
    Clin Cancer Res; 1998 May; 4(5):1125-34. PubMed ID: 9607569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rapid development of drug resistance in human ovarian tumor xenografts after a single treatment with melphalan in Vivo.
    Caffrey PB; Zhang Y; Frenkel GD
    Anticancer Res; 1998; 18(4C):3021-5. PubMed ID: 9713503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma.
    Köpf-Maier P
    Anticancer Res; 1999; 19(1A):493-504. PubMed ID: 10226588
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumour necrosis factor enhances the therapeutic effect of mitoxantrone in human ovarian cancer xenograft.
    Noviello E; Cimoli G; Cosimi A; Allievi E; Galletti P; Parodi S; Russo P
    Cytokine; 1996 Apr; 8(4):330-3. PubMed ID: 9162224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
    Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
    Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumour effect of combination treatment with Sabarubicin (MEN 10755) and cis-platin (DDP) in human lung tumour xenograft.
    Bigioni M; Benzo A; Irrissuto C; Lopez G; Curatella B; Maggi CA; Manzini S; Crea A; Caroli S; Cubadda F; Binaschi M
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):621-9. PubMed ID: 18038274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the N-(hydroxymethyl)melamines as antitumour agents: mechanism of action studies.
    Coley HM; Brooks N; Phillips DH; Hewer A; Jenkins TC; Jarman M; Judson IR
    Biochem Pharmacol; 1995 May; 49(9):1203-12. PubMed ID: 7763301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and biological evaluation of rebeccamycin analogues modified at the imide moiety.
    Animati F; Berettoni M; Bigioni M; Binaschi M; Cipollone A; Irrissuto C; Nardelli F; Olivieri L
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5013-7. PubMed ID: 22749423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Antitumor activity and pharmacological properties of furizil].
    Stukov AN; Kraĭz BO; Aleksandrov VA; Ivin BA; Filov VA
    Vopr Onkol; 1985; 31(5):52-4. PubMed ID: 4013130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.